CA2871398C - Injectable formulation of a benzothiophene compound for use in the treatment and prevention of a central nervous system disorder - Google Patents

Injectable formulation of a benzothiophene compound for use in the treatment and prevention of a central nervous system disorder Download PDF

Info

Publication number
CA2871398C
CA2871398C CA2871398A CA2871398A CA2871398C CA 2871398 C CA2871398 C CA 2871398C CA 2871398 A CA2871398 A CA 2871398A CA 2871398 A CA2871398 A CA 2871398A CA 2871398 C CA2871398 C CA 2871398C
Authority
CA
Canada
Prior art keywords
compound
injectable preparation
salt
dihydrate
benzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2871398A
Other languages
English (en)
French (fr)
Other versions
CA2871398A1 (en
Inventor
Tetsuya Sato
Takuya MINOWA
Yusuke HOSHIKA
Hidekazu TOYOFUKU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49483139&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2871398(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CA2871398A1 publication Critical patent/CA2871398A1/en
Application granted granted Critical
Publication of CA2871398C publication Critical patent/CA2871398C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2871398A 2012-04-23 2013-04-23 Injectable formulation of a benzothiophene compound for use in the treatment and prevention of a central nervous system disorder Active CA2871398C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261636932P 2012-04-23 2012-04-23
US61/636,932 2012-04-23
US201361791896P 2013-03-15 2013-03-15
US61/791,896 2013-03-15
PCT/JP2013/061950 WO2013161830A1 (ja) 2012-04-23 2013-04-23 注射製剤

Publications (2)

Publication Number Publication Date
CA2871398A1 CA2871398A1 (en) 2013-10-31
CA2871398C true CA2871398C (en) 2021-04-27

Family

ID=49483139

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2871398A Active CA2871398C (en) 2012-04-23 2013-04-23 Injectable formulation of a benzothiophene compound for use in the treatment and prevention of a central nervous system disorder

Country Status (31)

Country Link
US (6) US20150086632A1 (OSRAM)
EP (1) EP2868318B2 (OSRAM)
JP (1) JP6249944B2 (OSRAM)
KR (1) KR102168263B1 (OSRAM)
CN (4) CN110638752A (OSRAM)
AR (1) AR090775A1 (OSRAM)
AU (1) AU2013253518B2 (OSRAM)
BR (1) BR112014026398B1 (OSRAM)
CA (1) CA2871398C (OSRAM)
CO (1) CO7151499A2 (OSRAM)
CY (1) CY1123195T1 (OSRAM)
DK (1) DK2868318T4 (OSRAM)
EA (1) EA026124B1 (OSRAM)
ES (1) ES2727454T5 (OSRAM)
HR (1) HRP20190841T4 (OSRAM)
HU (1) HUE043686T2 (OSRAM)
IL (1) IL235211A0 (OSRAM)
IN (1) IN2014DN08870A (OSRAM)
JO (1) JO3524B1 (OSRAM)
LT (1) LT2868318T (OSRAM)
MX (1) MX361722B (OSRAM)
MY (1) MY169099A (OSRAM)
NZ (1) NZ630255A (OSRAM)
PH (1) PH12014502366A1 (OSRAM)
PL (1) PL2868318T5 (OSRAM)
PT (1) PT2868318T (OSRAM)
SG (2) SG10201608684QA (OSRAM)
SI (1) SI2868318T2 (OSRAM)
TW (1) TWI641395B (OSRAM)
UA (1) UA118084C2 (OSRAM)
WO (1) WO2013161830A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20210047A1 (ar) * 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
WO2017106641A1 (en) * 2015-12-17 2017-06-22 Assia Chemical Industries Ltd. Solid state forms of brexpiprazole
WO2017134038A1 (en) 2016-02-01 2017-08-10 Hexal Ag Anhydrate-free polymorphically pure micronized crystalline brexpiprazole dihydrate for use in intramuscular injectable sustained release formulations
WO2017208251A1 (en) * 2016-05-31 2017-12-07 Cipla Limited A new stable polymorph of brexpiprazole and process for preparation thereof
US20200093821A1 (en) 2016-08-16 2020-03-26 Hexal Ag Pharmaceutical Compositions of a Benzothiophene Compound
WO2018141886A1 (en) * 2017-02-02 2018-08-09 Hexal Aktiengesellschaft Crystalline brexpiprazole
EA202192646A1 (ru) * 2019-03-28 2021-12-09 Оцука Фармасьютикал Ко., Лтд. Лиофилизированная композиция, содержащая соединение бензоазепина
JPWO2021029020A1 (OSRAM) * 2019-08-13 2021-02-18
CN117794517A (zh) * 2021-09-07 2024-03-29 四川科伦药物研究院有限公司 注射用布瑞哌唑长效制剂及其制备方法
CN117214053A (zh) * 2023-10-17 2023-12-12 海南卫康制药(潜山)有限公司 一种注射用头孢呋辛钠肌注混悬液的粒度测定方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3402195B2 (ja) * 1997-05-14 2003-04-28 千寿製薬株式会社 再分散性の良い水性懸濁液剤
KR20010012188A (ko) 1997-05-14 2001-02-15 요시다 쇼지 재분산성이 양호한 수성 현탁액제
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
WO2002015878A1 (fr) * 2000-08-25 2002-02-28 Senju Pharmaceutical Co., Ltd. Preparations en suspension aqueuse
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
JP4836797B2 (ja) * 2003-10-23 2011-12-14 大塚製薬株式会社 放出制御性無菌注射アリピプラゾール製剤および方法
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
CA2622758A1 (en) 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
TW200808375A (en) 2006-05-12 2008-02-16 Otsuka Pharma Co Ltd Hydrogel suspension and manufacturing process thereof
TWI415629B (zh) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
MX2010001311A (es) * 2007-07-31 2010-04-21 Otsuka Pharma Co Ltd Metodo para producir una suspensi?n de aripiprazol y formulacion liofilizada.
JP5581227B2 (ja) * 2008-03-11 2014-08-27 アルコン リサーチ, リミテッド 硝子体内注射のための低粘度、高凝集トリアムシノロンアセトニド懸濁剤
EP2367572B1 (en) * 2008-11-19 2018-08-29 Merial, Inc. Formulations comprising ceftiofur and benzyl alcohol
MX344235B (es) * 2010-08-24 2016-12-07 Otsuka Pharmaceutical Co Ltd * Suspension y composicion en torta que contiene un derivado de carbostirilo y aceite de silicona y/o un derivado de aceite de silicona.
JP5893616B2 (ja) * 2010-10-18 2016-03-23 大日本住友製薬株式会社 注射用徐放性製剤
PL2685979T3 (pl) * 2011-03-18 2017-02-28 Alkermes Pharma Ireland Limited Kompozycje farmaceutyczne do wstrzykiwania zawierające środek nierozpuszczalny w wodzie, środek przeciwpsychotyczny, laurynian sorbitanu i polisorbat 20
JP2012232958A (ja) 2011-05-09 2012-11-29 Otsuka Pharmaceut Co Ltd 注射製剤
WO2013142205A1 (en) * 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Also Published As

Publication number Publication date
PH12014502366B1 (en) 2015-01-12
AU2013253518B2 (en) 2017-10-05
CY1123195T1 (el) 2021-10-29
SI2868318T2 (sl) 2022-04-29
PL2868318T5 (pl) 2022-06-20
SG11201406775UA (en) 2014-12-30
US20220305007A1 (en) 2022-09-29
DK2868318T3 (da) 2019-06-03
NZ630255A (en) 2016-05-27
KR102168263B1 (ko) 2020-10-21
KR20150003336A (ko) 2015-01-08
CN104363912A (zh) 2015-02-18
JPWO2013161830A1 (ja) 2015-12-24
AU2013253518A1 (en) 2014-11-06
SI2868318T1 (sl) 2019-06-28
LT2868318T (lt) 2019-07-25
EP2868318B1 (en) 2019-03-06
TW201406401A (zh) 2014-02-16
EP2868318A1 (en) 2015-05-06
HRP20190841T1 (hr) 2019-07-26
WO2013161830A1 (ja) 2013-10-31
CN111888329A (zh) 2020-11-06
JO3524B1 (ar) 2020-07-05
CN110638752A (zh) 2020-01-03
CA2871398A1 (en) 2013-10-31
US20180092910A1 (en) 2018-04-05
ES2727454T5 (es) 2022-05-13
MX361722B (es) 2018-12-14
TWI641395B (zh) 2018-11-21
CO7151499A2 (es) 2014-12-29
EP2868318A4 (en) 2015-12-09
US20200163960A1 (en) 2020-05-28
US10624889B2 (en) 2020-04-21
EA026124B1 (ru) 2017-03-31
AR090775A1 (es) 2014-12-03
ES2727454T3 (es) 2019-10-16
US20240277702A1 (en) 2024-08-22
IL235211A0 (en) 2014-12-31
MY169099A (en) 2019-02-18
BR112014026398B1 (pt) 2022-11-29
PT2868318T (pt) 2019-06-07
MX2014012734A (es) 2015-04-10
SG10201608684QA (en) 2016-12-29
BR112014026398A2 (pt) 2017-06-27
UA118084C2 (uk) 2018-11-26
US20150086632A1 (en) 2015-03-26
HRP20190841T4 (hr) 2022-03-04
HK1205678A1 (en) 2015-12-24
EA201491937A1 (ru) 2015-03-31
PL2868318T3 (pl) 2019-09-30
CN107536802A (zh) 2018-01-05
EP2868318B2 (en) 2022-01-26
DK2868318T4 (da) 2022-03-28
PH12014502366A1 (en) 2015-01-12
JP6249944B2 (ja) 2017-12-20
US20250241909A1 (en) 2025-07-31
IN2014DN08870A (OSRAM) 2015-05-22
HUE043686T2 (hu) 2019-09-30

Similar Documents

Publication Publication Date Title
US20240277702A1 (en) Injectable formulation
EP1675573B2 (en) Controlled release sterile injectable aripiprazole formulation and method
EP2841054B1 (en) Injectable preparation
KR101727085B1 (ko) 과증식성 질환, 자가면역 질환 및 심장 질환을 치료하기 위한 3-퀴뉴클리디논을 포함하는 수용액
HK1205678B (en) Injectable formulation
JP2012232958A (ja) 注射製剤
HK40038894A (en) Injectable formulation
HK40020106A (en) Injectable formulation
HK40007947A (en) Injectable preparation
HK1206988B (en) Injectable preparation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180423